Surprisingly, BTK T474 and L528 are frequently mutated in CLL patients treated with the covalent inhibitors Zanubrutinib and Tirabrutinib (Figure 1d, Blombery et al., 2022; Jackson et al., 2023; Handunnetti et al., 2019). Here, BTK is linked to B-cell chronic lymphocytic leukemia.